Literature DB >> 12050100

Lack of association between adipose tissue distribution and IGF-1 and IGFBP-3 in men and women.

Robert E Schoen1, Jeff Schragin, Joel L Weissfeld, F Leland Thaete, Rhobert W Evans, Clifford J Rosen, Lewis H Kuller.   

Abstract

Insulin, insulin-like growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), and obesity, and in particular visceral obesity, are putative cancer risk factors. Little is known, however, about the relationship between IGFs and obesity. We investigated the relationship between adipose tissue distribution and IGF-1 and IGFBP-3. Single-slice abdominal computed tomography scanning through the L4-L5 interspace was used to measure visceral adipose tissue (VAT) and subcutaneous adipose tissue (SQAT) in 432 community-based subjects (267 men, 165 women; ages, 55-77), participating in a cancer screening trial. Insulin, IGF-1, IGFBP-3, and the ratio of IGF-1:IGFBP-3, measured by radioimmunoassay, were compared with age, body mass index, absolute and relative VAT and SQAT, and total abdominal fat. We found that men had a higher mean IGF-1 (129.5 versus 108.9 ng/ml; P < 0.0001) and more VAT (201.5 cm(3) versus 166.6 cm(3); P < 0.0001) than women. In men and women, there was no correlation between IGF-1, IGFBP-3, or the ratio of IGF-1:IGFBP-3 with body mass index, total fat, VAT or SQAT, or fasting insulin. In contrast, fasting insulin was highly correlated to all measures of obesity (P = 0.0001). We conclude that obesity, adipose tissue distribution, and in particular VAT are not correlated with IGF-1, IGFBP-3, or the molar ratio of IGF-1:IGFBP-3. The lack of association between obesity and the IGF-1 axis suggests that the IGF-1 axis is not a likely mediator between VAT and disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050100

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  13 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link?

Authors:  Douglas A Corley
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

3.  Altered metabolism and resistance to obesity in long-lived mice producing reduced levels of IGF-I.

Authors:  Adam B Salmon; Chad Lerner; Yuji Ikeno; Susan M Motch Perrine; Roger McCarter; Christian Sell
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-02-03       Impact factor: 4.310

4.  Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors.

Authors:  Melinda L Irwin; Anne McTiernan; Leslie Bernstein; Frank D Gilliland; Richard Baumgartner; Kathy Baumgartner; Rachel Ballard-Barbash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-12       Impact factor: 4.254

5.  Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults.

Authors:  David Berrigan; Nancy Potischman; Kevin W Dodd; Stephen D Hursting; Jackie Lavigne; J Carl Barrett; Rachel Ballard-Barbash
Journal:  Growth Horm IGF Res       Date:  2008-09-21       Impact factor: 2.372

6.  Visceral adipose tissue: relations between single-slice areas and total volume.

Authors:  Wei Shen; Mark Punyanitya; ZiMian Wang; Dympna Gallagher; Marie-Pierre St-Onge; Jeanine Albu; Steven B Heymsfield; Stanley Heshka
Journal:  Am J Clin Nutr       Date:  2004-08       Impact factor: 7.045

7.  Growth Hormone Dynamics in Healthy Adults Are Related to Age and Sex and Strongly Dependent on Body Mass Index.

Authors:  Ferdinand Roelfsema; Johannes D Veldhuis
Journal:  Neuroendocrinology       Date:  2015-07-28       Impact factor: 4.914

8.  Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability.

Authors:  Helen Swede; Thomas E Rohan; Herbert Yu; Joseph C Anderson; Richard G Stevens; Jane Brokaw; Joel Levine; Bruce M Brenner; Carl D Malchoff; Valerie B Duffy; Devon C Pleau; Daniel W Rosenberg
Journal:  Cancer Causes Control       Date:  2008-12-09       Impact factor: 2.506

9.  In case of obesity, longevity-related mechanisms lead to anti-inflammation.

Authors:  Mehmet Salih Kaya; Fahri Bayıroglu; Leyla Mis; Dide Kilinc; Bahat Comba
Journal:  Age (Dordr)       Date:  2013-12-04

10.  Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial.

Authors:  Hsin-Chieh Yeh; Nisa M Maruthur; Nae-Yuh Wang; Gerald J Jerome; Arlene T Dalcin; Eva Tseng; Karen White; Edgar R Miller; Stephen P Juraschek; Noel T Mueller; Jeanne Charleston; Nowella Durkin; Ahmed Hassoon; Dina G Lansey; Norma F Kanarek; Michael A Carducci; Lawrence J Appel
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.